1. Radical Resection for Second EGFR-mutated Primary Lung Cancer Following Immune Checkpoint Inhibitor Monotherapy for Stage IV Lung Adenocarcinoma
- Author
-
Taku Hatakeyama, Tatsuru Ishikawa, Kaoru Nishiyama, Midori Hashimoto, Ryota Horibe, Takeyuki Sawai, Yasunari Takakuwa, Hiromitsu Domen, and Masaaki Satoh
- Subjects
Lung Neoplasms ,Adenocarcinoma of Lung ,Pembrolizumab ,Exon ,Growth factor receptor ,Biopsy ,Internal Medicine ,medicine ,Humans ,Stage (cooking) ,Lung cancer ,Immune Checkpoint Inhibitors ,Lung ,Aged ,medicine.diagnostic_test ,business.industry ,General Medicine ,medicine.disease ,ErbB Receptors ,medicine.anatomical_structure ,Mutation ,Cancer research ,Adenocarcinoma ,Female ,business - Abstract
A 78-year-old woman with multiple lung nodules, epithelial growth factor receptor (EGFR) exon 20 insertion mutations, and diagnosed with advanced lung adenocarcinoma (cT4N3M1a, stage IVA), was referred to our hospital. She received immune checkpoint inhibitor (ICI) therapy. The therapy showed remarkable antitumor effects; only a single nodule remained in the right upper lobe. The nodule was diagnosed as adenocarcinoma through a biopsy. We subsequently performed right upper lobectomy for multiple primary lung cancer (MPLC). The surgical specimen contained EGFR exon 19 deletion mutations and not exon 20 insertion mutations.
- Published
- 2022
- Full Text
- View/download PDF